

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/622,353	09/12/2000		John A. Arbuckle	0457-PCT-US	4766
•	7590	12/17/2002			
David B Ran				EXAMINER	
7100 N W 62nd Avenue Darwin Building				TUNG, JOYCE	
Johnston, IA	50131			ART UNIT	PAPER NUMBER
				1637	
				DATE MAILED: 12/17/2002	( Š

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No. 09/622,353 Applicant(s)

Arbuckle et al.

Examiner

Joyce Tung

Art Unit 1637



	The IVIAILING DATE of this communication appears	on the cover sneet with the correspondence address
	for Reply	
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE3 MONTH(S) FROM
mailing - If the p - If NO p	g date of this communication. period for reply specified above is less than thirty (30) days, a reply within th period for reply is specified above, the maximum statutory period will apply a	and will expire SIX (6) MONTHS from the mailing date of this communication.
- Any re	to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	· ·
Status 1) 🔀	Responsive to communication(s) filed on <i>Oct 8, 20</i>	02
2a) 🔀	This action is <b>FINAL</b> . 2b) $\square$ This act	
	·	
3)∐	closed in accordance with the practice under Ex pair	except for formal matters, prosecution as to the merits is rte Quayle, 1935 C.D. 11; 453 O.G. 213.
	tion of Claims	
4) (X)	Claim(s) <u>1-21</u>	is/are pending in the application.
4	la) Of the above, claim(s)	is/are withdrawn from consideration.
5) 🗆	Claim(s)	is/are allowed.
6) 💢	Claim(s) <u>1-21</u>	is/are rejected.
7) 🗆	Claim(s)	is/are objected to.
8) 🗆	Claims	are subject to restriction and/or election requirement.
Applica	ition Papers	
9) 🗆	The specification is objected to by the Examiner.	
10) 🗆	The drawing(s) filed on is/are	a) $\square$ accepted or b) $\square$ objected to by the Examiner.
	Applicant may not request that any objection to the d	rawing(s) be held in abeyance. See 37 CFR 1.85(a).
11)	The proposed drawing correction filed on	is: a) $\square$ · approved b) $\square$ disapproved by the Examiner.
	If approved, corrected drawings are required in reply t	to this Office action.
12)	The oath or declaration is objected to by the Exami	ner.
	under 35 U.S.C. §§ 119 and 120	•
	Acknowledgement is made of a claim for foreign pr	riority under 35 U.S.C. § 119(a)-(d) or (f).
a) ∟	☐ All b)☐ Some* c)☐ None of:	
	1. ☐ Certified copies of the priority documents hav	
	2. ☐ Certified copies of the priority documents hav	
	<ol> <li>Copies of the certified copies of the priority do application from the International Burea ee the attached detailed Office action for a list of the</li> </ol>	au (PCT Rule 17.2(a)).
	Acknowledgement is made of a claim for domestic	•
a) □	7	
15)	Acknowledgement is made of a claim for domestic	
Attachm	-	, , , , , , , , , , , , , , , , , , , ,
1) 🗌 No	otice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).
2) 🗌 No	otice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)
3) Inf	formation Disclosure Statement(s) (PTO-1449) Paper No(s).	6}

Application/Control Number: 09/622,353 Page 2

Art Unit: 1637

## Response to Amendment

- 1. The amendment filed 10/8/2002 has been entered.
- 2. The rejection of claim 2 under 35 U.S.C. §112, second paragraph is withdrawn.
- 3. Claims 1, 4-7, 9-13 and 15-21 remain rejected under 35 U.S.C. §103(a) as being unpatentable over Briggs et al. (5,962,764) in view of Lindemann et al. (5,958738).

Applicant's arguments filed 10/8/2002 have been fully considered but they are not persuasive because Applicants argue that in Briggs et al. one can determine an otherwise unknown phenotype for a gene of known sequence, while the claimed invention enables one to isolate an unknown sequence given a known phenotype and Briggs et al. employ primers to the transposable element and to the known genetic sequence. The limitation "isolate an unknown sequence given a known phenotype" is not in the claim language. However, if the claim is amended to include the limitations as discussed in the response filed 10/8/2002 with due support in the specification, the instant rejection will be withdrawn.

Applicants further argue that Briggs et al. do not disclose using primers to anneal to the adapter and transposable element and Lindemann et al. also do not disclose using primers to anneal to the adapter and transposable element. However, in the claims, there are two primers in which one of the primers anneals to the adapter sequence and the another primer anneals to the transposable element. Accordingly, Applicants arguments are not commensurate with the scope of the claimed invention.

Applicants also argue that Lindemann et al. teach a method for obtaining polynucleotides comprising sequences that differ between two populations of DNA. It appears that the claimed invention uses two populations of DNA that differs in the sequences (See claim 1, step(b)).

Thus, the rejection is maintained.

Regarding the request in the response filed April 11, 2002 that examiner detail for record why the inoperability of Lindemann et al. as modified for the claimed invention fails to disqualify it as prior art. It is unclear what is meant by disqualifying as prior art and its inoperability. However, the reference of Lindemann et al.'s filling date is March 24, 1997 which is before the priority date claimed, 2/17/1998. In addition, the reference of Lindemann et al. was applied with the reference of Straus et al. under 35 U.S.C. 103(a) in the rejection mailed 6/21/2001 and the rejection was withdrawn. All US patents are operable.

4. Claims 2-3, 8 and 14 remain rejected under 35 U.S.C. 103(a) over Briggs et al. and Lindemann et al., further in view of Schanble et al. and Halverson et al.

Since claims 2-3, 8 and 14 depend from claim 1 which is not allowable over the prior art as discussed in section 3 above. the rejection of claims 2-3, 8 and 14 is maintained.

5. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE

MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

MONTHS of the mailing date of this final action and the advisory action is not mailed until after

Application/Control Number: 09/622,353 Page 4

Art Unit: 1637

the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

6. Any inquiries concerning this communication or earlier communications from the examiner should be directed to Joyce Tung whose telephone number is (703) 305-7112. The examiner can normally be reached on Monday-Friday from 8:00 AM-4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached at (703) 308-1119 on Monday-Friday from 10:00 AM-6:00 PM.

Any inquiries of a general nature or relating to the status of this application should be directed to the Chemical/Matrix receptionist whose telephone number is (703) 308-0196.

7. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Art Unit 1637 via the PTO Fax Center located in Crystal Mall 1 using (703) 305-3014 or 308-4242. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989).

Joyce Tung

December 11, 2002

GARY BENZION, PH.D

SUPERVISORY PATENT EXAMINER